Business & Finance Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion
Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in vivo CAR-T.
By
· April 20, 2026 · 1 min read
This article was originally published by
CNBC Top News
and is republished here under license.
Kelonia is developing technology to reprogram patients’ T-cells inside the body so those cells can attack cancer, called in vivo CAR-T.
Like this:
Like Loading...
Related
Italy’s government expects the country’s budget deficit to fall below the European Union limit this year despite a downward revision…
By
· April 20, 2026 · 1 min read
Fitch Ratings sees the possibility of a restructuring of Mozambique’s debt likely ahead of any new deal being secured with…
By
· April 20, 2026 · 1 min read
Cleveland-Cliffs Inc.’s chief executive officer said improving US steel prices and stronger demand from the American auto industry are taking…
By
· April 20, 2026 · 1 min read
Leave a Reply